Aurobindo Pharma Limited Business Intelligence Report
Aurobindo Pharma Limited Business Intelligence Report
Quality Scores
Latest Quarterly Earnings Summary
Loading latest quarter…
AI Summary
Aurobindo Pharma is India's 2nd largest listed pharma company by revenue and a dominant player in the US generic market. The company has successfully transitioned from an API-focused manufacturer to a diversified global formulations powerhouse with strong vertical integration. Despite steady top-line growth, the last decade has been marked by significant margin volatility due to US pricing pressure and raw material fluctuations. Recent strategic shifts towards biologics and specialized injectables suggest a move up the value chain. However, capital efficiency as measured by ROCE has seen a…
Key Changes in FY2026
The company has undergone a significant transformation from a semi-synthetic penicillin manufacturer to a global generic formulations powerhouse. The last decade saw a steady move up the value chain from simple APIs to complex generics, injectables, and most recently, biologics and CDMO services. Geographically, Aurobindo successfully diversified from being US-centric to establishing a top-10 presence in eight European countries. The strategic pivot toward specialty medicines and high-barrier products like biosimilars (TheraNym facility) aims to mitigate the pricing pressure inherent in the US oral solids market. This evolution is evidenced by the rising R&D spend and the increasing complexity of US FDA filings. The business has successfully transitioned through several regulatory…
Management Commentary
Management shows strong operational execution and scale-up capabilities, maintaining the #1 US generic volume spot for an Indian firm. They possess a clear vision for 'Aurobindo 2.0' centered on complex generics and CDMO services, evidenced by the anchor customer MSD for their new facility. However, communication regarding USFDA warning letters and regulatory hurdles at various plants has historically been reactive. The leadership has successfully navigated numerous patent cliffs but must now prove they can manage the higher regulatory scrutiny of biologics. Transparency on subsidiary performance and inter-company loans remains an area for improvement.
Financial Highlights
Revenue has grown at a 10-year CAGR of 9%, but profit growth has lagged at 6%, indicating margin compression over time. Operating Profit Margins fluctuated between 15% and 23%, recently stabilizing around 20% in FY24. The net profit of FY21 was abnormally high (INR 5,334 Cr) due to exceptional items/divestments, making historical comparisons tricky without adjustments. While absolute EBITDA is rising, the company struggles with a persistent increase in depreciation and interest costs. The return on equity has compressed from high teens to a modest 10-11% range, reflecting a heavy asset base that is not yet yielding peak returns.
Major Opportunities
- Largest Indian generics company in the USA by volume
- Successfully diversified into European markets (Top 10 in 8 countries)
- Strong vertical integration with a massive API portfolio
Major Risks
- Poor sales growth of 6.32% over the last five years
- Extremely weak ROE of 10% over the last 3 years
- Negative free cash flow in the most recent fiscal year
About Aurobindo Pharma Limited's Annual Report & Financial Performance
The latest Aurobindo Pharma Limited annual report (FY2026) is the company's flagship annual disclosure, filed with NSE / BSE. It covers the full-year business review, management discussion & analysis, audited financial statements, the director's report, the corporate governance and auditor's reports, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This Business Intelligence Hub consolidates the official filings with AI-generated financial analysis so investors can see how revenue, operating margin, cash flow quality, capex, dividends, net debt and management outlook have changed — without reading the entire filing.
What this Aurobindo Pharma Limited research covers
- Fundamental & business analysis
- Financial statements & performance
- Management commentary & discussion
- Corporate governance & auditor report
- Cash flow analysis & capital allocation
- Valuation analysis & business quality
- Growth analysis & competitive position
- Risk, SWOT & moat analysis
- Quarterly earnings & conference-call summary
- Sector, industry & peer comparison
- Latest official company filings
- Business outlook & long-term growth
Aurobindo Pharma Limited — Frequently Asked Questions
Explore more Aurobindo Pharma Limited research
AI Top Insights — Premium
Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.